As the use of modern weight loss medications spikes across the United States, questions about insurance coverage and affordability are becoming increasingly common. In Howard County, Maryland, the public school system recently spent over $8 million on weight loss drugs for employees, but will soon restrict coverage to only those with diabetes. Officials say the decision was driven by rapidly rising costs, which escalated 600% over two years. The school system believes these steps will help avoid a nearly 20% increase in health insurance premiums for all participants.
The drugs in question, known by names like Ozempic, Wegovy, and Mounjaro, were originally intended to treat diabetes but are now widely prescribed to help with obesity and weight loss. Over a thousand employees and retirees were using these medications under the health plan, nearly 10% of the insured population. Some, like a special education teacher who requested anonymity, say they rely on these drugs for more than just weight loss, reporting better energy and lower cholesterol. Many express concern that, without insurance, the drugs could become unaffordable for those who need them.
Medical experts like Dr. Jung-Im Shin from Johns Hopkins University argue these medications can prevent obesity-related conditions such as diabetes, and worry that limiting coverage only to diabetic patients could leave others at risk. Employers across the country face similar dilemmas, as spending on GLP-1 medications increases and insurance providers weigh new limits on coverage to control costs.
Meanwhile, in Hawaii, Senator Kurt Favella is making efforts to expand insurance coverage for weight loss drugs. Favella, who lost significant weight himself using Mounjaro for diabetes, introduced a bill that would require Medicaid to cover GLP-1 drugs for people struggling with obesity, even if they do not have diabetes. The measure is gaining attention, as Hawaii’s Department of Health reports over half the adult population has an unhealthy Body Mass Index, and a quarter are considered obese.
Supporters of the expanded coverage emphasize the broader health benefits and potential to fight obesity at an earlier stage. Critics among employers and health plan administrators focus on the unpredictable costs, noting that pricing and demand for these medications change rapidly. As legislative debates continue and employer policies adjust, the question of who should pay for weight loss drugs remains unsettled, with implications for millions seeking to improve their health.
